1. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
- Author
-
Zayac, Adam S., Landsburg, Daniel J., Hughes, Mitchell E., Bock, Allison M., Nowakowski, Grzegorz S., Ayers, Emily C., Girton, Mark, Hu, Marie, Beckman, Amy K., Li, Shaoying, Medeiros, L. Jeffrey, Chang, Julie E., Stepanovic, Adam, Kurt, Habibe, Sandoval-Sus, Jose, Ansari-Lari, M. Ali, Kothari, Shalin K., Kress, Anna, Xu, Mina L., Torka, Pallawi, Sundaram, Suchitra, Smith, Stephen D., Naresh, Kikkeri N., Karimi, Yasmin H., Epperla, Narendranath, Bond, David A., Farooq, Umar, Saad, Mahak, Evens, Andrew M., Pandya, Karan, Naik, Seema G., Kamdar, Manali, Haverkos, Bradley, Karmali, Reem, Oh, Timothy S., Vose, Julie M., Nutsch, Heather, Rubinstein, Paul G., Chaudhry, Amina, and Olszewski, Adam J.
- Abstract
•HGBL-NOS is a highly heterogeneous category; PFS (55% at 2 years) did not significantly differ between R-CHOP and intensified regimens.•A dual-expressor (MYC and BCL2) immunophenotype and TP53alterations, but not MYCalterations, were significantly associated with worse PFS.
- Published
- 2023
- Full Text
- View/download PDF